Most modern chemo-and radiotherapy treatments of human cancers use the DNA damage pathway, which induces a p53 response leading to either G1 arrest or apoptosis. However, such treatments can induce mutations and translocations leading to secondary malignancies or recurrent disease, which often have a poor prognosis because of resistance to therapy. Here we report that 5,6-dichloro-1-b-D-ribofuranosylbenzimidazole (DRB), an inhibitor of CDK7 TFIIH-associated kinase, CKI and CKII kinases, blocking RNA polymerase II in the early elongation stage, triggers p53-dependent apoptosis in human colon adenocarcinoma cells in a transcription independent manner. The fact that DRB kills tumour-derived cells without employment of DNA damage gives rise to the possibility of the development of a new alternative chemotherapeutic treatment of tumours expressing wild type p53, with a decreased risk of therapy-related, secondary malignancies.
Introduction
In recent years cure rates for a number of cancers have improved considerably. This is due, in part, to the use of multi-agent chemotherapy, often given in high-dose (Dunton, 1997; Gordon, 1997; Hiddemann, 1995; Pui and Crist, 1995; Reuss et al., 1996; van Basten et al., 1997) . It therefore becomes even more important to consider the long-term eects of treatment. Reports over the last 10 years have described new, therapyrelated, malignancies induced by certain treatment regimens, which often have a poor prognosis because of resistance to therapy (Aas et al., 1996; Elli et al., 1996; Felix et al., 1996; Hsiao et al., 1994) . Most cytotoxic drugs, and radiotherapy, induce DNA damage in tumour cells with the objective of activating p53 as a transcription factor, which then activates genes involved in inducing G1 arrest or apoptosis (Lane et al., 1995; Lowe et al., 1993a,b; . However, with such treatment, DNA damage is also induced in normal cells. It has been shown that alkylating agents and cisplatin caused unbalanced chromosomal aberrations (Pedersen-Bjergaard et al., 1990) , and epipodophyllotoxins (inhibitors of topoisomerase II) have been implicated in causing translocations involving chromosome bands 11q23 and 21q22, both of which have been associated with secondary malignancies (Elli et al., 1996; Pedersen-Bjergaard et al., 1991) . Recent analysis of resistant and recurrent tumours, provides strong evidence that a high percentage of them carry de novo p53 mutations (Aas et al., 1996; Hsiao et al., 1994; Lowe et al., 1994) .
p53 is a tumour suppressor protein which functions to control genomic integrity (Gottlieb and Oren, 1996; Ko and Prives, 1996; Levine, 1997) . Failure to do so, because of p53 gene mutations inactivating the protein, ultimately leads to cancer. About 50% of human cancers are associated with mutations in the p53 gene. p53 reacts to DNA damage by transforming from the latent to the activated form, inducing activated protein cascades which ultimately arrest cells in G1, preventing those with a damaged genome from entering the S phase. Where this damage cannot be repaired, apoptosis, or programmed cell death, is triggered. However, despite intensive research in the p53 ®eld, the exact signal which leads to p53 activation is still unknown. It has been shown that p53 dependent apoptosis can be induced in the absence of transcriptional activation of p53 regulated genes (Caelles et al., 1994) , and that up-regulation of p53 levels within the cell is a transcription independent process, regulated at the transcriptional level (Fu and Benchimol, 1997; Fu et al., 1996; Mosner et al., 1995) .
Recent reports have shown that abnormalities in transcription can also induce a p53 response followed by G1 arrest or apoptosis (Caelles et al., 1994; Linke et al., 1996; Tishler et al., 1993; Yamaizumi and Sugano, 1994) . Treatment of cells with RNA polymerase inhibitors such as actinomycin D and a-amanitin results in accumulation of p53 (Caelles et al., 1994; Tishler et al., 1993; Yamaizumi and Sugano, 1994) . Depletion of the nucleotide triphosphates in cells treated with ribonucleotide biosynthesis inhibitors results in p53 dependent G1 arrest (Linke et al., 1996) . Similar results were shown for 5-¯uorouracil (5-FU) which can induce p53 dependent apoptosis in intestinal epithelial cells (Pritchard et al., 1997) . Such a situation provides a unique opportunity to employ transcription-blocking agents as potential p53 response inducers in cancer chemotherapy without putting patients under genotoxic stress. However, a-amanitin is an extremely toxic agent, whereas actinomycin D and 5-FU can also induce DNA damage via other mechanisms. It has also been shown that short Increase in apoptosis up to 40 mg/ml after which the eect reached plateau. Percentages (+s.d.) are the average of at least three experiments. The FACScan experiments were performed at least three times treatment of human ®broblasts with 5,6-dichloro-1-b-D-ribofuranosylbenzimidazole (DRB), which eciently inhibits transcription at the early elongation stage by inhibiting CDK7 kinase, and preventing RNA polymerase II to proceed after initiation (Dubois et al., 1994; Yankulov et al., 1995; Zandomeni et al., 1982) , can induce a transient burst in p53 levels (Andera and Wasylyk, 1997) .
In our present study we investigated the cytotoxicity of DRB in p53 wild-type and mutant expressing colon adenocarcinoma cell lines. Colon cancer is a leading cause of death in the Western world and one of the most untreatable and therapy resistant cancers (Gryfe et al., 1997) . The molecular genetics of this cancer involves mutations of tumour suppressor genes APC (adenomatous polyposis coli) on chromosome 5q and p53 on chromosome 17p. Inactivating mutations of both alleles of the APC gene is one of the earliest events in colon carcinogenesis, and still provides an opportunity to exploit the p53 response pathway to treat colon cancer at an early stage (Baker et al., 1990) , although this may require improvements in the detection of early stage disease.
Human colon adenocarcinoma cell lines representing three major classes of p53 status in human colon cancers were used throughout this study, LS174T cells which express functional wt p53, HT29, SW480 and SW620 cell lines expressing a mutant of p53 (mutation R273H) and SW48 cells expressing a DNA contact mutant of p53 (R248W) . The two mutants represent common`hotspot' mutations (10% for arginine 273 and 15% for arginine 248) in human colon and other cancers (Hainaut et al., 1998) .
Continuous treatment with DRB reproducibly induced accumulation and stabilization of p53 in LS174T (wt p53) and SW48 (R248W p53) cell lines. In HT29, SW480 and SW620 cells (R273H p53) there was no up-regulation of already over-expressed p53. However, only LS174T cells containing wild type p53 were able to undergo dose-dependent DRB-induced apoptosis, which was abrogated by transfecting LS174T cells with a dominant negative structural mutant of p53 (p53 M237I). Taken together these data indicate that (i) functional wild type p53 is required to induce transcription independent apoptosis, (ii) phosphorylation of p53 by CDK7 and CKII is not required for this function and (iii) protein ± protein interaction, rather than p53 transcription repressor activity, play an important role when RNA synthesis is blocked. Our results indicate that DRB treatment is a potentially novel cancer chemotherapeutic strategy, capable of employing the p53-dependent apoptotic pathway without inducing genotoxic stress, thereby decreasing the risk of secondary malignancies.
Results

Cytotoxicity of 5,6-dichloro-1-b-Dribofuranosylbenzimidazole (DRB)
In order to assess whether DRB was cytotoxic, we treated a panel of colon adenocarcinoma cell lines at dierent doses and exposures. LS174T, HT29, SW48, SW480 and SW620 colon adenocarcinoma cells were exposed to 80 mg/ml DRB for up to 72 h and cells were analysed for apoptosis by FACS analysis and DNA agarose gel-electrophoresis. Results for LS174T, HT29 and SW48 cells are shown in Figure 1 .
DRB treatment resulted in apoptosis in LS174T cells, as shown by the increase in the sub G1 fraction in the DNA pro®les of LS174T cells (Figure 1a ), the appearance of nucleosomal DNA degradation ( Figure  1d ) and the cleavage of poly (ADP-ribose) polymerase (PARP) (Figure 1e ). The induction of apoptosis in Figure 2 Growth arrest and viability of LS174T, HT29, SW48 cells. Cells were treated with 80 mg/ml DRB, and cell numbers were counted in a haematocytometer. Viability was assessed by Trypan blue dye exclusion, and expressed as the ratio of viable cells to cell number. Growth inhibition was plotted as the ratio of viable treated cells to viable untreated cells. Percentages (+s.d.) are the average of at least three experiments To test the dose response relationship for DRB, we exposed LS174T cells to 10, 20, 40 and 80 mg/ml DRB for 72 h and compared the sub G1 fraction. As shown in Figure 1f , the apoptotic fraction increased with concentration up to 40 mg/ml when the dose response reached plateau. Although the apoptotic eect was maximal at 40 mg/ml in LS174T cells, 80 mg/ml DRB failed to induce apoptosis in HT29 and SW48 cells (Figure 1b,c,d ). DRB treatment did result in prolonged growth arrest in HT29 and SW48 cells (Figure 2a ), but without loss of viability (Figure 2b ), or any marked eects on the cell cycle distribution (results for HT29 and SW48 cells are shown in Figure 1b,c,d ).
DRB blocks RNA synthesis in LS174T, HT29 and SW48 cells
In order to assess whether the dierence in cytotoxicity was due to the ability of DRB to block RNA synthesis in the dierent cell lines, we exposed LS174T, HT29 and SW48 colon adenocarcinoma cells to 80 mg/ml DRB and monitored the amount of [5, H]uridine incorporation into RNA after dierent exposure times. An RNA synthesis block was apparent from the decreased incorporation of [5, H]uridine relative to untreated cells (Figure 3 ) and was the same for all cell lines treated. Although DRB is a speci®c RNA polymerase II inhibitor, incorporation of labeled uridine dropped below 10% to that of control cells within 2 h of exposure and remained below 10% during the 24 h investigated.
P53 status aects the response to DRB
Although RNA synthesis was blocked in all treated cells, only LS174T cells responded to DRB treatment by undergoing apoptosis. Treatment of HT29 and SW48 cells resulted in prolonged growth arrest without induction of apoptosis. A possible reason for this result could be that gene products involved in the cascades leading to apoptosis were mutated or deleted in these cell lines. We therefore assessed the p53 status by immunoprecipitation with the conformational antibodies PAb240 (recognizing only the mutant) and PAb1620 (recognizing only the wild-type conformation). LS174T and SW48 cells expressed correctly folded p53 protein, whereas HT29 cells expressed p53 with a mutant conformation (Figure 4a ). p53 mutant R273H was not immunoprecipitated by the speci®c conformational antibody Pab1620 which recognizes wild type conformation of p53. Thus, p53 mutant R273H also belongs to the class of structural mutants which cannot adopt wild type protein conformation. This would be consistent with previous in vitro data (Rolley et al., 1995) and the stability and up-regulated levels of the mutant p53 protein in HT29 cells.
Next, we analysed whether p53 levels in LS174T, HT29 and SW48 were aected by DRB exposure. The cells were treated with 80 mg/ml DRB and p53 levels were assessed by Western immunoblotting at regular intervals. An increase in p53 levels in LS174T cells was apparent after 4 h of DRB treatment (Figure 4b ). This increased up to 24 h, after which a decline in p53 levels could be seen, concomitant with an increase in the number of apoptotic cells. p53 levels were also increased in LS174T cells exposed to 20 and 40 mg/ml DRB (data not shown). The increased levels of p53, however, did not result in the up-regulation of p53 target gene products p21, hdm2, Bax and FAS (data not shown). In contrast to DNA damaging agents, which did cause transcriptional activation of p21 and hdm2 (RH Poele unpublished data). Interestingly, the level of Bax and Fas in untreated LS174T cells were barely detectable by immunoblotting (results not shown). In SW48 cells the highest levels of p53 could be observed 4 h into treatment after which the signal diminished. In the HT29 cell line the over-expressed levels of p53 did not change upon exposure to DRB. These data suggest that DRB induced apoptosis is a p53 dependent process. To further verify the dependence on wild-type p53 to induce apoptosis when transcription is blocked, we transfected the LS174T cell line with a dominant negative structural mutant of p53 (p53 M237I). As can be seen in Figure 4c the expression of a dominant negative of p53 abrogated DRB induced apoptosis. Apoptosis was not blocked completely, but comparing apoptosis in LS174T cells (Figure 1a ) with the transfected cell line (Figure 4c) shows that expression of a dominant negative p53 signi®cantly reduced apoptosis. That induction of apoptosis was not entirely blocked is probably due to the fact that most structural mutants of p53 do not have a complete dominant negative eect on cellular wild-type p53 (Williams et al., 1995) .
The eect of DRB in LS174T cells is reversible
In order to investigate if the eect of DRB on p53 levels in LS174T cells could be reversed, allowing surviving cells to cycle again, we treated LS174T cells at dierent drug concentrations and exposure-duration, after which the drug medium was removed and the cells were recultured in drug-free medium. At 24 h intervals cells were harvested and analysed for apoptosis by FACS analysis and for p53 levels by Western immunoblotting. In cells that were still viable, treatment with DRB was reversible, with cells recovering after withdrawal of DRB and re-culturing in drug free medium (Figure 5a ). LS174T cells which were cultured in the presence of 20 mg/ml DRB started to recover immediately after withdrawal of DRB as can be seen in the decline of the sub G1 fraction with recovery time and normalization of the DNA pro®le (Figure 5a ). Cells exposed at concentrations of 10 and 20 mg/ml for 72 h showed a 50% drop in the sub G1 fraction within 48 h, while those exposed to 40 mg/ml required 120 h recovery to show a 50% sub G1 decrease, and cells incubated with 80 mg/ml DRB showed no recovery in 120 h (Figure 5b ). Analysis of the recovery pro®les according to both duration and concentration of treatment suggested that DRB concentration had the greatest impact on recovery. Although the dose response curve with regard to apoptosis reached plateau at a concentration of 40 mg/ml, increasing the concentration above this negatively aected recovery. Drug withdrawal also aected the p53 levels in LS174T cells. Upon drug withdrawal the p53 levels decreased within 24 h, and continued to decrease until at 96 h recovery, p53 levels were similar to those of untreated control cells ( Figure  5c ). This is consistent with the observation that short treatment with DRB leads only to a transient burst of p53 level with no consequence for cell survival (Andera and Wasylyk, 1997) .
Recovery of surviving cells is not due to clonal selection of a resistant population
The recovery of LS174T cells after DRB exposure was not due to clonal selection of cells resistant to DRB. Cells that recovered after withdrawal were subcultured for 2 weeks and growth curves were measured. Cells exposed to 20, 40 (72 h) and 80 (48 h, cells exposed for 72 h did not recover) mg/ml of DRB had indistinguishable growth curves from control cells (Figure 6a ). When recovered cells were again exposed to the same concentration of DRB, they showed similar sensitivity as measured by apoptosis as during the ®rst exposure (Figure 6b ).
Discussion
The molecular mechanism of DRB action involves speci®c inhibition of protein kinases CKI, CKII (Shugar, 1994) and TFIIH-associated CDK7 (Yankulov et al., 1995) . Both CKII and CDK7 kinases have been demonstrated to phosphorylate the p53 protein.
In the case of CKII, serine 392 is a target for phosphorylation, but it was shown not to be required for p53 dependent G1 arrest (Fiscella et al., 1994) . It was also shown that phosphorylation of Ser392 by CKII can selectively regulate p53 dependent transcriptional repression but not transactivation (Hall et al., 1996) . CDK7 phosphorylation of p53 at the Cterminus has been shown to enhance the ability of p53 to bind sequence speci®c target DNA elements, and may activate p53 as a transcription factor (Lu et al., 1997) . Another site of p53 phosphorylation by CDK7 was mapped to serine 33 at the N-terminus (Ko et al., 1997) . The mutants R273H and R248W as well as other tumour derived mutants have also been shown to be phosphorylated by CDK7 at similar levels to wild type p53 (Ko et al., 1997) .
Here we show that blocking transcription from RNA polymerase II in human colon adenocarcinoma cells expressing wild type p53 by treatment with DRB, eciently induces a p53 response, which leads to apoptosis. The fact that DRB blocks transcription is consistent with the absence of up-regulation of p53 target gene products such as p21, hdm2, Bax and FAS. The absence of p21 expression will shift the outcome of treatment from G1 arrest towards the apoptotic program and at the same time the absence of negative feedback regulation of p53 by hdm2 will allow the cells to stabilize high levels of p53 after induction (Haupt et al., 1997; Kubbutat et al., 1997) . Our data provides evidence that phosphorylation of p53 by CKII and CDK7 is not required for stabilization of p53 levels, nor is it required for p53-dependent apoptosis when RNA synthesis by RNA polymerase II is blocked.
Our data also indicate that DRB-induced apoptosis is a p53-dependent process. The cell lines HT29, carrying mutant p53 (R273H) and SW48, carrying p53 mutant R248W, did not respond to DRB treatment by undergoing apoptosis. The inability of HT29 cells to undergo apoptosis following DRB treatment is not due to a defect in the apoptotic pathway. HT29 cells readily undergo apoptosis following exposure to the topoisomerase inhibitors SN-38 and VP-16 without change in p53 levels. (RH Poele unpublished data). Although there was a temporary rise in p53 levels in SW48 cells, contrary to HT29 cells where p53 levels remained the same, this did not result in apoptosis. Introduction of a dominant negative structural mutant of p53 (p53 M237I) abrogated DRB induced apoptosis. Although apoptosis was not completely blocked, expression of p53 M237I signi®cantly reduced apoptosis. Others have suggested that expression of p53 structural mutants generally does not have a complete dominant negative eect on cellular wild-type p53 (Williams et al., 1995) , which may explain that some apoptosis was observed in the transfected cells.
Our data show that both R273H and R248W mutants of p53 are de®cient in transcription independent apoptosis. Their inability to function is therefore not simply due to removal of the important speci®c DNA contact residues . The structure of the p53 central core domain with p53 binding protein 2 (p53BP2) has shown that the same residues involved in speci®c DNA contact also play a crucial role in the interaction with the SH3 domain of p53BP2. Curiously, both mutations R248W and R273H disrupt binding to the SH3 domain of p53BP2 (Gorina and Pavletich, 1996) . One can speculate that protein ± protein interaction during p53 dependent apoptosis in the absence of transcription may involve p53 binding to SH3 domains of some proteins. P53BP2 can potentially serve as such an intermediate and it has been shown to bind bcl2 in vitro (Naumovski and Cleary, 1996) . Our results demonstrate for the ®rst time that p53 dependent apoptosis in the absence of transcription cannot be explained by p53 acting as a repressor of genes necessary for cell survival (Caelles et al., 1994) , since both types of p53 mutant studied were unable to induce apoptosis, even though transcription was repressed during DRB treatment of the cells. We suggest that the transcription independent p53 dependent apoptotic pathway may rely more on protein ± protein interaction than on p53 dependent repression of certain genes.
Normal tissues express wild-type p53, and can be expected to undergo apoptosis upon exposure to DRB. In contrast with a recent report (Koumenis and Giaccia, 1997) , we were able to demonstrate DRB induced apoptosis in phytohaemagglutinin stimulated lymphocytes from healthy volunteers (results not shown), showing that transformation of cells is not necessary to sensitize them to DRB. Oncogenic transformation however, might increase the sensitivity of cells to DRB, which in turn would improve the therapeutic index of the drug. The importance of wildtype p53 was con®rmed by demonstrating DRBinduced apoptosis in the breast adenocarcinoma cell line MCF7 and the lymphoid cell line U937 (data not shown).
Importantly, when exposure to DRB in LS174T cells was stopped, by re-culturing into drug-free media, viable cells recovered in a dose and time dependent manner. In the clinical setting, this would allow normal tissues to recover prior to the next cycle of treatment. The recovery of LS174T cells after DRB exposure, however, was not due to clonal selection of cells resistant to DRB. Cells that recovered after withdrawal of DRB, had indistinguishable growth characteristics from control cells and were as sensitive to the second exposure to DRB as they were originally.
Unlike radiotherapy and most commonly used chemotherapy, DRB treatment does not invoke DNA damage (Ljungman et al., 1999) . DRB blocks transcription by inhibiting CDK7 kinase, preventing RNA polymerase II transcription after initiation (Dubois et al., 1994; Yankulov et al., 1995; Zandomeni et al., 1982) . This results in apoptosis in a p53 dependent manner, without genotoxic stress, which would be expected to greatly decrease the potential risk of therapy related malignancies. Although colon carcinoma cell lines have been used in this study, the fact that apoptosis after exposure to DRB is dependent on the presence of functional p53 suggests that it may also be useful in tumours which typically have normal p53, such as testicular teratomas and leukaemias. In addition to this, such tumours, which have high cure rates, are those in which therapy-related malignancies are more common, and in which a non-DNA directed approach would be bene®cial.
It is also possible that such a therapeutic strategy may prove useful in the treatment of pre-malignant tumours where p53 is likely to be functional, in tumours with changes in DNA repair capacity, such as mutations in brca1, brca2 in breast cancer (Casey, 1997; Krainer et al., 1997) and msh2, mlh1, pms1 and pms2 in hereditary non-polyposis colon cancer (HNPCC) (Aaltonen and Peltomaki, 1994; Fishel et al., 1993; Froggatt et al., 1996) and in patients with chronic DNA repair de®ciency syndromes such as xeroderma pigmentosum, Cockayne syndrome and ataxia-telangiectasia (Elli et al., 1996; Meyn, 1995; Morgan and Kastan, 1997) . Finally, together with a possible clinical potential of DRB treatment, DRBinduced p53-dependent apoptosis could be an excellent experimental model to study activation and stabilization of p53 in the absence of DNA damage.
Materials and methods
Cell culture and exposure to 5,6-Dichloro-1-b-Dribofuranosylbenzimidazole (DRB)
Colon adenocarcinoma cell lines, LS174T, HT29, SW48, SW480, SW620 were cultured in RPMI 1640 medium supplemented with 10% foetal bovine serum, penicillin 100 U/ml and streptomycin 100 mg/ml (Gibco ± BRL). LS174T cells were transfected with the pcDNA3 vector (Invitrogen) containing the coding region for p53 M237I, using the Lipofectin system (Gibco ± BRL). Transfected cells were selected in Geneticin (Gibco ± BRL), and stable clones were used in the experiments. Twenty-four hours prior to treatment 7 ml of 2610 5 cells/ml were seeded in culturē asks. DRB (Sigma) was dissolved in dimethylsulfoxide (DMSO; Sigma) and stock solutions were diluted in medium just before treatment. The ®nal concentration of DMSO in the cell culture medium was 0.2% in all cases, including control cells. The cells were incubated at 378C in a humidi®ed atmosphere containing 5% CO 2 .
DNA analysis by¯ow cytometry
The DNA content of the cells was determined using a rapid one-step DNA staining technique, with the¯uorescent dye propidium iodide (Sigma), and apoptotic cells were discriminated by controlled extraction of low molecular weight DNA (Darzynkiewicz et al., 1994) . Fluorescence was measured using a FACScan and results were analysed using Lysys II software (Beckton Dickinson).
DNA isolation and gel electrophoresis
DNA was isolated according to the protocol described by Eldadah et al. (1996) , using Wizard Minipreps DNA Puri®cation Resin (Promega). 500 ng of DNA was loaded for each sample. DNA was visualized by UV illumination and photographed on Polaroid 665 positive/negative ®lm (Sigma). 4 exponentially growing cells were seeded in each well of a 96 well plate in a volume of 200 ml and grown overnight. Next, the medium was replaced with medium containing dierent concentrations of DRB. Cells were incubated for dierent periods of time, and pulse chased with 1 mCi [5, H]uridine (Amersham) per well for 1 h. The cells were lysed and nucleic acid was transferred to glass ®bre mats in a Tomtec cell harvester 96 (Tomtec). Mats were encased, and scintillant was added. Sealed bags were put in cassettes, and b-emission in each well was measured using a 1450 Microbeta liquid scintillation counter (Wallac). RNA synthesis in treated samples was expressed as a percentage of control cells.
Immunoprecipitation and Western immunoblotting
The p53 status in the cell lines was tested by immuno precipitation with the conformational antibodies Pab1620 and Pab240. IP samples and cell lysates were blotted onto PVDF membrane (Bio Rad) followed by immunostaining with Pab240 for p53 and C2-10 (Pharmingen) for PARP as primary antibodes and HRP-labelled rabbit anti-mouse antibody (DAKO) as a secondary. After washing immunoreactive bands were visualized by the ECL detection system (Amersham).
